Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Biocon share price today rose 3% after Biocon Biologics received US FDA approval for diabetes drug Kirsty, the first interchangeable biosimilar to NovoLog in the US. Get latest updates on Biocon ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

With the stock currently priced at Rs 400.15, Biocon shows a positive trend in today's early trading session on NIFTY MIDCAP 150.

Clinical trials have demonstrated that both biosimilars match the reference product's quality, safety and efficacy standards.

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...